## AFL: Aflac Incorporated - XLF: Financial Services

### Executive Summary

VALUE thesis: PEG 0.93 indicates fundamental undervaluation. Quality metrics strong (ROE 16%). Caution: momentum weakening (-2.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($105.58)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 8
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Ameriflex, Aflac (AFL) team up to deliver CDH and spending account admin for public sector**
- Source: Stock Titan | 20251202T090000 | Bullish | Relevance: 100%
- Ameriflex and Aflac have announced a partnership where Ameriflex will administer consumer-directed health (CDH) services for Aflac in the public sector market. This collaboration aims to provide seamless delivery of spending accounts like FSAs and HSAs, enhancing Aflac's offerings and customer experience for public sector clients. Both companies emphasize their shared commitment to excellent service and innovative solutions to deliver value and financial protection.

**2. Is Aflac Stock Underperforming the Nasdaq?**
- Source: inkl | 20251202T122131 | Somewhat-Bearish | Relevance: 100%
- Aflac (AFL) is underperforming the Nasdaq, with its stock up only 2.5% in the last three months compared to the Nasdaq Composite's 8.5% rise. Despite long-term underperformance relative to the Nasdaq, Aflac has outperformed peer MetLife (MET) and maintains a consensus "Hold" rating with analysts. The company recently declared a dividend increase, marking its 43rd consecutive year of dividend growth.

**3. Ameriflex and Aflac Partner to Deliver Seamless Consumer Directed Health Care Administration in the Public Sector Market**
- Source: Yahoo Finance | 20251202T080000 | Bullish | Relevance: 100%
- Ameriflex and Aflac have partnered to streamline consumer-directed health care (CDH) administration in the public sector market. Ameriflex will serve as Aflac's administrative partner for CDH services, initially focusing on spending accounts like FSAs and HSAs. This collaboration aims to provide enhanced customer experience and deliver comprehensive benefit administration solutions to Aflac's public sector clients.

**4. How a park bench meeting led to Aflacâ€™s $200 million mascot idea**
- Source: Fortune | 20251201T135700 | Bullish | Relevance: 96%
- The Aflac duck campaign, launched in 2000 after an ad agency heard ducks that sounded like the company name in Central Park, significantly boosted Aflac's brand recognition and share price. CEO Dan Amos was initially hesitant but the campaign led to a 621% run-up in share price and increased the company's valuation by nearly $200 million. The Aflac duck's success is attributed to its universal appeal and memorability.

**5. Zacks Industry Outlook Highlights Aflac, Unum Group, Globe Life and Trupanion**
- Source: Yahoo Finance | 20251203T143900 | Bullish | Relevance: 93%
- The Zacks Accident and Health Insurance industry is expected to grow due to increased underwriting exposure and demand for supplemental health products, despite challenges like pricing pressure and rising medical costs. Key players like Aflac, Unum Group, Globe Life, and Trupanion are highlighted for their strategic advancements, strong financial performances, and adoption of technology. The industry overall shows weak near-term prospects due to a negative earnings outlook but is leveraging technology and improved claims frequency for long-term growth.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-17 | Morgan Stanley | $118 | $113 | +4% |
| 2025-11-07 | Wells Fargo | $109 | $107 | +2% |
| 2025-11-07 | Evercore ISI Gr | $111 | $110 | +1% |
| 2025-11-05 | JP Morgan | $101 | $100 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-17 | Morgan Stanley | main | Equal-Weight |
| 2025-11-07 | Wells Fargo | main | Equal-Weight |
| 2025-11-07 | Evercore ISI Gr | main | Underperform |
| 2025-11-05 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.18M) |
| Sells | 10 ($3.46M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Japan Post Holdings : 10.0% (0.0%)
- Vanguard Group Inc: 9.6% (-0.8%)
- Blackrock Inc.: 7.4% (+0.1%)
- State Street Corpora: 4.6% (+0.1%)
- Wells Fargo & Compan: 2.1% (-24.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.9% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $3.5M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 5 raises (avg +2%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.93 indicates undervaluation relative to growth. Quality metrics strong (margin 24%). Balance sheet: strong liquidity (48.2x). Insider selling cluster ($3.5M in 90 days), potential headwind. Institutional flow bearish (6 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $58.8B |
| Beta | 0.66 |
| 52W Range | $96.95 - $115.84 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.93 |
| Forward P/E | 14.8 |
| Current P/E | 14.4 |
| YoY Growth | -2.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -1.1% to -4.0% (-2.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.0pp (needs >4.0% for momentum thesis). Underperforming sector by 4.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.02x) but short-term weakness (below SMA20). RSI neutral at 44. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.03% (CS: 15) | Weak |
| RSI_14 | 43.6 | Neutral |
| MACD Histogram | -0.44 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 0.988x | Below |
| vs SMA200 | 1.023x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $109.04
- **Stop Loss:** $105.58 (3.2% risk)
- **Target:** $115.96 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 274
- **Position Value:** $29,876.96
- **Portfolio %:** 29.88%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-04 (Est: $1.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.78 | $2.49 | +40.2% |
| 2025Q2 | $1.71 | $1.78 | +4.3% |
| 2025Q1 | $1.67 | $1.66 | -0.8% |
| 2024Q4 | $1.62 | $1.56 | -3.5% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*